TY - JOUR
T1 - Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma
AU - de Haan, Jorine
AU - van Thienen, Johannes V.
AU - Casaer, Michael
AU - Hannivoort, Rebekka A.
AU - van Calsteren, Kristel
AU - van Tuyl, Minke
AU - van Gerwen, Mathilde M.
AU - Debeer, Anne
AU - Amant, Frédéric
AU - Painter, Rebecca C.
PY - 2018
Y1 - 2018
N2 - Targeted therapies have drastically changed the management of metastatic melanoma and have shown encouraging results on tumour progression but are also known for their high rates of adverse reactions. In general, targeted therapies are contraindicated during pregnancy due to concerns about teratogenesis. For the BRAF V600 inhibitor vemurafenib, the available literature about the effects on human pregnancy is limited to a single case report. In patients with metastatic melanoma that wish to continue their pregnancy, targeted therapies like vemurafenib offer the only possibility of improving maternal outcome. In this article, we report on a pregnant woman with metastatic melanoma who was treated with vemurafenib during pregnancy and experienced a fatal adverse reaction.
AB - Targeted therapies have drastically changed the management of metastatic melanoma and have shown encouraging results on tumour progression but are also known for their high rates of adverse reactions. In general, targeted therapies are contraindicated during pregnancy due to concerns about teratogenesis. For the BRAF V600 inhibitor vemurafenib, the available literature about the effects on human pregnancy is limited to a single case report. In patients with metastatic melanoma that wish to continue their pregnancy, targeted therapies like vemurafenib offer the only possibility of improving maternal outcome. In this article, we report on a pregnant woman with metastatic melanoma who was treated with vemurafenib during pregnancy and experienced a fatal adverse reaction.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85042136446&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/29606950
U2 - https://doi.org/10.1159/000487128
DO - https://doi.org/10.1159/000487128
M3 - Article
C2 - 29606950
SN - 1662-6575
VL - 11
SP - 119
EP - 124
JO - Case reports in oncology
JF - Case reports in oncology
IS - 1
ER -